¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦20ȸ µ¿°è±¹Á¦Çмú´ëȸ(2ÀÏÂ÷) : 2024-01-13

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦20ȸ µ¿°è±¹Á¦Çмú´ëȸ(2ÀÏÂ÷) : 2024-01-13
±³À°ÀÏÀÚ : 2024-01-13
±³À°Àå¼Ò : ¼­¿ï½Å¶óÈ£ÅÚ ´ÙÀ̳ʽºÆ¼ ¿Ü 3°³·ë

±³À°ÁÖÁ¦ : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦20ȸ µ¿°è±¹Á¦Çмú´ëȸ(2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
´ã´çÀÚ : Á¶¿¹¸®
¿¬¶ôó : 02-582-8222  

À̸ÞÀÏ : yehc@kscvi.org

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 28 ½Ã°£ 2ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í - Àü¹®ÀÇ,°³¿øÀÇ,ÀϹÝÀÇ:(ÇöÀåµî·Ï)60,000¿ø - ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,ÀÇ·á±â»ç,ÀÇ´ë»ý,±ºÀÇ°ü,°øÁߺ¸°ÇÀÇ,ÀÓ»óº´¸®»ç,Àǹ«±â·Ï»ç:(ÇöÀåµî·Ï)50,000¿ø - »ê¾÷ü,±âŸ:(ÇöÀåµî·Ï)120,000¿ø - ÇÐȸ Á¤È¸¿ø(Àü³âµµ ȸºñ¿Ï³³ÀÚ): ¹«·á


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 08:30~08:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Vascular Access Complication - Endovascular Girst, and Then Surgery ¼­¿ë¼º(¸íÁöº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 08:40~08:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Vascular Access Complication - Surgery Is the First Option °øÁØÇõ(ÀÎõ¼¼Á¾º´¿ø)

Åä·Ð 01¿ù 13ÀÏ Main Arena 08:50~09:00 Discussion ()

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 09:00~09:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Coronary Perforation or Rupture - Coil or Stent Graft Is First ½Å»óÈÆ(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 09:10~09:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Coronary Perforation or Rupture - Open and Bypass Is the First Option ÀÌÁØÈ£(¼º±Õ°üÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Main Arena 09:20~09:30 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Main Arena 09:30~09:35 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 08:30~08:42 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Consensus Statement for De-escalation or Abbreviation of DAPT(Dual Antiplatelet Therapy) in ACS9Acute Coronary Syndrome) Patients Á¤¿µÈÆ(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 08:42~08:54 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) De-escalation Strategy in HBR(High Bleeding Risk) Patients ¹Ú¸¸¿ø(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 08:54~09:06 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Escalation Strategy in Patients with High Thrombotic Risk ÃßÀºÈ£(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 09:06~09:18 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Long-term Antiplatelet Strategy after 1 Years in ACS(Acute Coronary Syndrome) Patients ¼Û¿µºó(¼º±Õ°üÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Symposium Arena 09:18~09:30 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Symposium Arena 09:30~09:35 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 08:30~08:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) 1-stent vs. 2-stenting ÀÌÇöÁ¾(ºÎõ¼¼Á¾º´¿ø)

Åä·Ð 01¿ù 13ÀÏ Presentation Arena 08:40~08:50 Discussion ()

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 08:50~09:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Case Wrap Up - 1-stent vs. 2-stenting ÀÌÇöÁ¾(ºÎõ¼¼Á¾º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 09:00~09:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Role of Intravascular Imaging in Bifurcation PCI(Percutaneous Coronary Intervention) ÀÌ»ó¿±(Áß¾ÓÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Presentation Arena 09:10~09:20 Discussion ()

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 09:20~09:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Case Wrap Up - Role of Intravascular Imaging in Bifurcation PCI(Percutaneous Coronary Intervention) ÀÌ»ó¿±(Áß¾ÓÀÇ´ë)

ÈÞ½Ä 01¿ù 13ÀÏ Presentation Arena 09:30~09:35 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 08:30~08:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Acute Chest pain - Review of 2021 ACC(American Colleage of Cardiology)/AHA(American Heart Association) Guidelines for Chest Pain ±Ç¿ìÂù(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 08:45~09:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Chronic Chest pain - Review of 2023 ACC(American Colleage of Cardiology)/AHA(American Heart Association) Guideline for Chronic Coronary Disease À̱âȯ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 09:00~09:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Interpret Non-invasive Tests from Exercise Tests to Nuclear Tests ±èÈ£¿¬(¿ï»êÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Early Career Arena 09:15~09:30 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Early Career Arena 09:30~09:35 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 09:35~09:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) What Should I Do If Image Drived Stent Underexpansion Is Observed? Á¶À±°æ(°Ô¸íÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 09:45~09:55 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) What Should I Do If Malapposition Is Observed after Stent Implantation? ±èº´±Ô(ÀÎÁ¦ÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Main Arena 09:55~10:05 Discussion ()

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 10:05~10:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) What Should I Do If Dissection or Hematoma Is Observed after Stent Implantation? ±èÁø¿ø(°í·ÁÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 10:15~10:25 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How I Use Intravascular Imaging Guidance in MINOCA(Myocardial Infarction with Non-obstructive Coronary Artery) or SCAD(Spontaneous Coronary Artery Dissection) Patients? À±ÇõÁØ(°è¸íÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Main Arena 10:25~10:35 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Main Arena 10:35~10:40 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 09:35~09:47 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) ÇʼöÀÇ·á Áö¿øÀ» À§ÇÑ ½ÉÇ÷°üÁúȯ ±Þ¿©°³¼± - NSTEMI(Non-ST Segment Elevation Myocardial Infarction) ±Þ¿©±âÁØ È®´ë ÀÌÀåÈÆ(°æºÏÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 09:47~09:59 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) ÇʼöÀÇ·á Áö¿øÀ» À§ÇÑ ½ÉÇ÷°üÁúȯ ±Þ¿©°³¼± - °ü»óµ¿¸ÆÀÇ ÀçºÐ·ù À̽·ü(Â÷ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 09:59~10:11 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) ÇʼöÀÇ·á Áö¿øÀ» À§ÇÑ ½ÉÇ÷°üÁúȯ ±Þ¿©°³¼± - ÇʼöÀÇ·á¿¡¼­ÀÇ ½ÉÇ÷°üÁúȯ Ä¡·áÇàÀ§ ±Þ¿© Á¶¿µ´ë(º¸°Çº¹ÁöºÎ º¸Çè±Þ¿©°ú)

Åä·Ð 01¿ù 13ÀÏ Symposium Arena 10:11~10:35 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Symposium Arena 10:35~10:40 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 09:35~09:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) History of CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention) and Its Evidences in the Literature ±¹Çüµ·(ÇѾçÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 09:45~09:55 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Review of Histopathology of CTO(Chronic Total Occlusion) Á¶Á¤·¡(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 09:55~10:05 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Pre- and Peri-procedural Imaging for CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention) ½Å»óÈÆ(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 10:05~10:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Equipments for CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention) and Basic Guidewire Skills Ȳº´Èñ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 10:15~10:25 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Advanced Guidewire Skills and Complication Management Á¶À翵(¿ø±¤ÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Presentation Arena 10:25~10:35 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Presentation Arena 10:35~10:40 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 09:35~09:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Patients with Acute Onset Chest Pain - Who Should Be Sent for Invasive Coronary Evaluation ¾È¼ö¿¬(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 09:50~10:05 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Patients with Chronic Coronary Disease - Who Should Be Sent for Invasive Coronary Evaluation ÃßÇö¿í(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 10:05~10:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Select Target Lesions for Coronary Revascularization? ÃÖ¿¬¿ì(¿ï»êÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Early Career Arena 10:20~10:35 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Early Career Arena 10:35~10:40 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 10:40~11:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) To be a Good Cardiologist: Regarding Mind Setting Á¶¼ºÁØ(°­ºÏ»ï¼ºº´¿ø Á¤½Å°Ç°­ÀÇÇаú)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 11:10~11:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Am I Good Cardiologist? Let¡¯s Check Out Our Life in Neurologists eye ¿ÀÁö¿µ(°Ç±¹´ëº´¿ø ½Å°æ°ú)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 11:40~12:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Life of Cardiologist: Correlation between Cardiology and Dive ÀÌÇöÁ¾(ºÎõ¼¼Á¾º´¿ø)

ÈÞ½Ä 01¿ù 13ÀÏ Main Arena 12:10~12:15 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 10:40~10:55 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Assess Difference in Variables? ¹®°Ç¿õ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 10:55~11:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Principle of Multivariable Snalysis (Linear, Logistic, Cox Proportional Hazard) ¾È¼Ò¿¬(ºÐ´ç¼­¿ï´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 11:10~11:25 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Use Propensity-score Analysis (Matching, IPTW(Inverse Probability of Treatment Weighting)) ¾ÈÀç¾ï(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 11:25~11:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Evaluated the Performance of Prediction Model °­´Üºñ(¼º±Õ°üÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Symposium Arena 11:40~12:10 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Symposium Arena 12:10~12:15 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 10:40~10:52 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Use of Closure Device in Peripheral Intervention ÁøÇÑ¿µ(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 10:52~11:04 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Closure Techniques after Intervention with Large Bore Access ¹Ú»ó¹Î(À»ÁöÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 11:04~11:16 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Prevention and Management of Hematoma after TRI(Transradial Intervention) ÇãÁ¤È£(°í½ÅÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 11:16~11:28 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Prevent Radial Artery Occlusion after TRI(Transradial Intervention) ÀÌ»ó¿±(Áß¾ÓÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Presentation Arena 11:28~11:40 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Presentation Arena 11:40~12:15 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 10:40~10:55 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antiplatelet Therapy as Secondary Prevention Á¤¹Î¼ö(°æºÏÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 10:55~11:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Lipid Lowering Therapy as Secondary Prevention ½ÂÀçÈ£(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 11:10~11:25 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antianginal Therapy for IHD(Ischemic Heart Disease) ¾ÈÇü¹ü(¼­¿ïÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Early Career Arena 11:25~11:40 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Early Career Arena 11:40~12:15 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 12:15~12:40 ARNI(Angiotensin Receptor Neprilysin Inhibior), Better Late than Never - How to Optimize the Revascularization and Medical Treatment for Ischemic Cardiomyopathy with HFrEF ÀÌÁÖ¸í(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 12:40~13:05 ARNI(Angiotensin Receptor Neprilysin Inhibior), Better Late than Never - The Significant Role of ARNI for Forgotten HFrEF Patients ÀÌÀåÈÆ(°æºÏÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Main Arena 13:05~13:15 Discussion ()

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 12:15~12:35 Update on Statin Therapy and LIPILOU Studies in Korea ÀÌ¿ëÁØ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 12:35~12:55 Beta-blocker Therapy in Patients with AMI: Are All ¥â-blockers the Same? ÇÑÁ¤±Ô(¼­¿ïÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Symposium Arena 12:55~13:15 Discussion ()

±âŸ 01¿ù 13ÀÏ Presentation Arena 12:15~12:18 Session Introduction ()

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 12:18~12:33 SAPIEN 3 Ultra Can Help Patient Life. Time. Management in TAVI(Transcatheter Aortic Valve Implantation) Journey - What Is PARTNER 3 5-year Data Implication? ¹Ú´ö¿ì(¿ï»êÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 12:33~12:48 SAPIEN 3 Ultra Can Help Patient Life. Time. Management in TAVI(Transcatheter Aortic Valve Implantation) Journey - Life. Time. Management Begins with SAPIEN 3 Ultra °íÀ±¼®(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 12:48~13:03 SAPIEN 3 Ultra Can Help Patient Life. Time. Management in TAVI(Transcatheter Aortic Valve Implantation) Journey - How to handle complex cases with SAPIEN 3 Ultra and make it successful. (Criteria : 1. SAPIEN 3 Ultra case only, 2. Complex case and good result) ÀÌÁ¾¿µ(¼º±Õ°üÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Presentation Arena 13:03~13:15 Q&A ()

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 12:15~12:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Update on Evidence-based Management of High Risk Patients with Dyslipidemia Á¶À±°æ(°è¸íÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 12:30~12:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Latest Trends in Dyslipidemia Management for Very High-risk ASCVD(Atherosclerotic Cardiovascular Disease) Patients ±è¹Îö(Àü³²ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 12:45~13:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Early and High-intensity LLT(Lipid-lowering Therapy) in Very High-risk ASCVD(Atherosclerotic Cardiovascular Disease) Patients with Dyslipidemia ¹®µ¿±Ô(¼º±Õ°üÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Early Career Arena 13:00~13:15 Discussion ()

±âŸ 01¿ù 13ÀÏ Main Arena 13:15~14:00 KSIC General Meeting ()

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 14:00~14:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Is iFR(Instantaneous Flow Ratio) the Same as FFR(Fractional Flow Reserve)? - Indeed! Yoshiaki Kawase(Gifu Heart Center. Japan)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 14:10~14:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Is iFR(Instantaneous Flow Ratio) the Same as FFR(Fractional Flow Reserve)? - Indeed! iFR is as important as FFR! ¾ÈÁ¤¹Î(¿ï»êÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Main Arena 14:20~14:30 Disccusion ()

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 14:30~14:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) OCT(Optical Coherence Tomography) vs. IVUS(Intravascular Ultrasonography): Does It Still Matter? ±è¿ëö(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 14:40~14:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Deep Dive into NIRS-IVUS(Near-Infrared Spectroscopy and Intravascular Ultrasound) Satoshi Mogi(Hamamatsu University Hospital. Japan)

Åä·Ð 01¿ù 13ÀÏ Main Arena 14:50~15:00 Disccusion ()

ÈÞ½Ä 01¿ù 13ÀÏ Main Arena 15:00~15:05 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 14:00~14:12 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Vascular Access and Closure Devices for Aortic Procedure À±¿µÁø(¿¬¼¼¿øÁÖÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 14:12~14:24 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Selection and Basic Manipulation of All EVAR(Endovascular Aneurysm Repair) Device ¹ÚÅñÔ(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 14:24~14:36 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Overcome of Complex Landing Zone and Tortuosity °í¿µ±¹(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 14:36~14:48 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Mangement of endoleak, type I & II ±ÇÁØÈ£(¿¬¼¼ÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Symposium Arena 14:48~15:00 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Symposium Arena 15:00~15:05 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 14:00~14:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) A 44 Year Old Male Presenting with Chest Pain that Started Two Days Ago ±è¿ëÀÌ(â¿ø°æ»ó´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 14:10~14:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) A Retrograde CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention) Case with Balloon Undilatable Lesion À̱âȯ(¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 14:20~14:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) A Step-by-step Guide for the Balloon Tip-in Technique to Perform a Retrograde Approach without Wire Externalization in Coronary Chronic Total Occlusion À̿뱸(ÇѾç´ëÇб³ ±¸¸®º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 14:30~14:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Mini-crush Technique: Cardiogenic Patient with Left Main Total Occlusion Supported by Extra Corporeal Membrane Oxygenation Á¤À¯Á¤(¿µ³²´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 14:40~14:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) A Patient with Cardiogenic Shock and Critical Left Main Stenosis Treated under Impella Mechanical Circulatory Support Device ÃÖ¿ø¼®(Sheikh Khalifa Specialty Hospital. UAE)

±âŸ 01¿ù 13ÀÏ Presentation Arena 14:50~15:00 °á°ú Áý°è ¹× ½Ã»ó ()

ÈÞ½Ä 01¿ù 13ÀÏ Presentation Arena 15:00~15:05 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 14:00~14:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Treat Culprit Lesion? - What Should Do and What Should Not Do? Á¤Áø(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 14:15~14:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Treat Non-culprit Lesion? - Review of Recent Trials ±Ç¿ìÂù(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 14:30~14:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Post-interventional Management - Review of GDMT(Guideline-directed medical therapy) from Guidelines ÀÌÁøÈ£(¿ï»êÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Early Career Arena 14:45~15:00 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Early Career Arena 15:00~15:05 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 15:05~15:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Current Evidence for M-Transcatheter Edge-to-Edge Repair, 2024 °­µµÀ±(¿ï»êÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 15:15~15:25 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Morphological Suitability of M-TEER(Mitral Valve Transcatheter Edge-to-edge Repair) in Primary MR(Mitral Regurgitation) Á¶Àͼº(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 15:25~15:35 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Heart Team Approach in M-TEER(Mitral Valve Transcatheter Edge-to-edge Repair): Case Based Learning ÃÖ±âÈ«(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 15:35~15:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) T-TEER(Triclip Tricuspid Valve Repair), Open a New Chapter in Tricuspid Valve Disease ¾ÈÁØÈ£(Àü³²ÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ Main Arena 15:45~16:05 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Main Arena 16:05~16:10 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 15:05~15:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Efficacy and Safety of Under-dose Non-vitamin K Antagonist Oral Anticoagulant with Atrial Fibrillation Undergoing PCI(Percutaneous Coronary Intervention): Insights from a Nationwide Population-based Cohort Study ¹ÚÁ¤¹Ì(µ¿¾Æ´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 15:15~15:25 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Developing a Machine Learning Model for Predicting 30-Day MACCE(Long-term Major Adverse Cardiac and Cerebrovascular Events) in Non-Cardiac Surgery Patients ¾ÈÇü¹ü(ºÐ´ç¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 15:25~15:35 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  High Platelet Reactivity Predicts Early Stent Thrombosis in Patients with DES(Drug-eluting Stent) Implantation ÀÓ¼öºó(°í·Á´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 15:35~15:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Long-term Clinical Outcomes of Paclitaxel-Coated Balloon Coronary Angioplasty: Data from the IRIS-DEB(Drug-Eluting Balloon Registry in Routine Clinical Practice) Registry Á¶»ó¿ë(¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 15:45~15:55 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Intravascular Imaging-Guided versus Angiography-Guided PCI(Percutaneous Coronary Intervention): Systematic Review and Meta-analysis of 24 Randomized Controlled Trials È«´ÙÀ§(¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø)

±âŸ 01¿ù 13ÀÏ Symposium Arena 15:55~16:05 °á°ú Áý°è ¹× ½Ã»ó ()

ÈÞ½Ä 01¿ù 13ÀÏ Symposium Arena 16:05~16:10 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 15:05~15:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Integrating Intravascular Imaging and Physiology-guided Assessment for Optimizing Therapeutic Strategies in Recurrent, Heavily Calcified Stenosis °­ÀçÈ£(°í·Á´ëÇб³ ±¸·Îº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 15:15~15:25 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Stumpless RCA(Right Coronary Artery) Ostium CTO(Chronic Total Occlusion) with Severe Calcification ±è´ë¿ø(°¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 15:25~15:35 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  A Case of Post-myocardial Infarction Ventricular Septal Defect Accompanied with ST-elevation Myocardial Infarction ±èâÈÆ(¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 15:35~15:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Angiographically Isolated Left Main Coronary Artery Disease Demonstrating Negative Remodeling in IVUS(Intravascular Ultrasonography) with a Grey-zone FFR(Fractional Flow Reserve) ¹Ú¿µ¼±(¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 15:45~15:55 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Magic Touch: Intervention for Stenosis, Plaque, and Ischemia without Devices Á¶ÇØÂù(¼­¿ï´ëÇб³º´¿ø)

±âŸ 01¿ù 13ÀÏ Presentation Arena 15:55~16:05 °á°ú Áý°è ¹× ½Ã»ó ()

ÈÞ½Ä 01¿ù 13ÀÏ Presentation Arena 16:05~16:10 Break Time ()

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 15:05~15:17 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) PTA(Percutaneous Transluminal Angioplasty) »ç·Êº° ±Þ¿© ±è¼ÒÁ¤(¼¼ºê¶õ½º ½ÉÀåÇ÷°üº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 15:17~15:29 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) AMI(Acute Myocardial Infarction) & CTO(Chronic Total Occlusion) ¼ö±â·á »è°¨ »ç·Ê ±è¼±¹è(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 15:29~15:41 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Rotational Atherectomy »è°¨ »ç·Ê Àå´ë¼®(¿ëÀμ¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 15:41~15:53 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) ÀÎÁ¤ ºñ±Þ¿© / ½ÅÀÇ·á¼ö°¡ ½Å¼³ ÀÓ¼¼¿µ(»ï¼º¼­¿ïº´¿ø)

Åä·Ð 01¿ù 13ÀÏ Early Career Arena 15:53~16:05 Discussion ()

ÈÞ½Ä 01¿ù 13ÀÏ Early Career Arena 16:05~16:10 Break Time ()

±âŸ 01¿ù 13ÀÏ Main Arena 16:10~16:15 SFR General Meeting ()

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 16:15~16:25 Cutting-edge Insights in the Use of DCB(Drug-coated Balloon) in De Novo Large Vessel Disease ½ÅÀº¼®(¿ï»êÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 16:25~16:35 Harnessing the Synergy: Hybrid Approach of DCB(Drug-coated Balloon) and DES(Drug-eluting Stent) in Multivessel Disease ±è¿ìÇö(ÇѾçÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 16:35~16:43 New Emerging Trial: REVERSE, DCB-MVD, SFR-GENISTA À̽ÂÇå(Àü³²ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ Main Arena 16:43~16:55 International DCB(Drug-coated Balloon) Consensus, Where Are We? Yoshinobu Onuma(National University of Ireland. Ireland)

Åä·Ð 01¿ù 13ÀÏ Main Arena 16:55~17:10 Discussion ()

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 16:10~16:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Clinical Effect through Simulation of Valvular Heart Disease Using Individualized 3-Dimensional Printing Model ±è´ë¿ø(°¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 16:20~16:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Cardiovascular Outcomes of Early Low-density Lipoprotein Cholesterol Goal Achievement in Patients with Atherosclerotic Cardiovascular Disease ±è¾Æ¶÷(¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 16:30~16:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Impact of the Residual Lipid Burden on the Clinical and Angiographic Outcomes after Percutaneous Coronary Intervention ¹Ú¼öÁ¤(ÇѾç´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 16:40~16:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Short-term Dual Antiplatelet Therapy Reduces Bleeding Risk without Increasing Ischemic Risk in Patients Undergoing Complex Percutaneous Coronary Intervention with Third-generation Drug-eluting Stents: A Post Hoc Analysis of the HOST-IDEA Trial À̱âȯ(¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Symposium Arena 16:50~17:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Impact of Intravascular Imaging in Percutaneous Coronary Intervention According to Underlying Atherothrombotic Risk ÇÏÁØÈ£(¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø)

±âŸ 01¿ù 13ÀÏ Symposium Arena 17:00~17:10 °á°ú Áý°è ¹× ½Ã»ó ()

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 16:10~16:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Valve in Valve TAVR(Transcatheter Aortic Valve Replacement) with BASILICA due to Prosthesis-patient Mismatch ±è¿ëÈñ(°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 16:20~16:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Case of a Patient with Arterial Occlusion of Four Extremities º¯ÀçÈ£(°¡Å縯ÀÇ´ë ÀÎõ¼º¸ðº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 16:30~16:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  A Case of Ruptured Mycotic Aortic Aneurysm Caused by Recurrent Urinary Tract Infection; Treated with Zone 2 Thoracic Endovascular Aneurysm Repair(TEVAR) and Antibiotics ¿Â´ë¿õ(°¡Å縯ÀÇ´ë ÀºÆò¼º¸ðº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 16:40~16:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  A Case of Drug-eluting Stent(DES) Implantation for Multiple Recurrences of In-stent Restenosis in Previously Implanted Bare Metal Stents(BMS) À̾翬(¿¬¼¼ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Presentation Arena 16:50~17:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥)  Percutaneous Retrieval of an Embolized Transcatheter Edge-to-edge Repair Clip in Left Atrium ÀÌÁøÈ£(¿ï»êÀÇ´ë ¾Æ»êº´¿ø)

±âŸ 01¿ù 13ÀÏ Presentation Arena 17:00~17:10 °á°ú Áý°è ¹× ½Ã»ó ()

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 16:10~16:22 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) NEW Devices (Wolverine & ROTAPRO) ¼Û°É¼ö(ºÐ´ç¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 16:22~16:34 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) EVAR(Endovascular Aneurysm Repair) with Heli-FX EndoAnchor System À̱Լº(´ëÀüÀ»Áö´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 16:34~16:46 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Introduction to the Special Benefits of DCBs(Drug-coated Balloons) Á¶¹ÎÁØ(ÃæºÏ´ëÇб³º´¿ø)

±³À°½Ã°£ 01¿ù 13ÀÏ Early Career Arena 16:46~16:58 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) LA(Left Atrial) Venting Procedure in ECMO(Extracorporeal Membrane Oxygenation) ¹Ú¼Ò¿¬(°Ç±¹´ëÇб³º´¿ø)

Åä·Ð 01¿ù 13ÀÏ Early Career Arena 16:58~17:10 Discussion ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦20ȸ µ¿°è±¹Á¦Çмú´ëȸ(2ÀÏÂ÷) : 2024-01-13""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2024³â 1Â÷ ´ëÇѺ¹°­°æ°£¼ö¼ú ½ÉÆ÷Áö¾ö : 2024-01-13
´ÙÀ½±Û ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦20ȸ µ¿°è±¹Á¦Çмú´ëȸ(1ÀÏÂ÷) : 2024-01-12
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20998 °æ±â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ °æÀÎÁöȸ Á¦7ȸ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-23 0 1 2024-06-16
20997 ¼­¿ï Á¦18ȸ ´ëÇѺñ°úÇÐȸ ½ÉÆ÷Áö¾ö : 2024-06-23 0 1 2024-06-16
20996 ÀÎõ ÀÎÇÏ´ëÇб³º´¿ø Á¦6ȸ ÀÎÇÏÇǺνÉÆ÷Áö¾ö : 2024-06-22 0 1 2024-06-16
20995 ¼­¿ï Á¦23ȸ Çѱ¹Á¤¸Æ°æÀ念¾çÇÐȸ Çмú´ëȸ ¹× 2024 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2024-06-22 0 1 2024-06-16
20994 ¼­¿ï 2024³â Á¦2Â÷ ´ëÇѳëÀÎÀÇÇÐ ¼¼ºÎÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-22 0 4 2024-06-16
20993 ¼­¿ï ´ëÇѼҾÆÀçÈ°¹ß´ÞÀÇÇÐȸ Çмú´ëȸ : 2024-06-22 0 0 2024-06-16
20992 °æ±â 2024³â ¾È¾ç½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-22 0 0 2024-06-16
20991 ¼­¿ï ´ëÇѼҾƳ»ºÐºñÇÐȸ Á¦18Â÷ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-22 0 0 2024-06-16
20990 ¼­¿ï 2024³â Çѱ¹ºÐ¼®½É¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-22 0 0 2024-06-16
20989 ¼­¿ï 2024 ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ ³ú½Å°æÁ¶Àý Moving Symposium : 2024-06-22 0 0 2024-06-16
20988 ¼­¿ï 2024 Á¦ 13ȸ ´ëÇѺñ´¢»ý½Ä±âÅëÇÕ±â´ÉÀÇÇבּ¸È¸ Çмú´ëȸ : 2024-06-22 0 15 2024-06-14
20987 Ãæ³² 2024³â ´ëÇÑ°í°üÀýÇÐȸ Áø·áÁöħ ½ÉÆ÷Áö¿ò : 2024-06-22 0 17 2024-06-14
20986 ±¤ÁÖ Á¦24ȸ ´ëÇÑôÃ߽Űæ¿Ü°úÇÐȸ È£³²Áöȸ Á¤±âÇмú´ëȸ : 2024-06-22 0 17 2024-06-14
20985 °æ±â ´ëÇÑÁ¾¾ç³»°úÇÐȸ KSMO Annual Academy for young oncologists(2ÀÏÂ÷) : 2024-06-22 0 12 2024-06-14
20984 °æºÏ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦43Â÷ ÇÏ°è±¹Á¦Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-22 0 10 2024-06-14
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷